Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - amantadine hydrochloride 100mg - capsule - 100 mg - active: amantadine hydrochloride 100mg excipient: ethyl hydroxybenzoate gelatin glycerol iron oxide red karion 83 opacode white a-8154 phosphatidylcholines, soya, hydrogenated rape oil sodium propyl hydroxybenzoate soya bean oil, hydrogenated   titanium dioxide yellow beeswax - treatment of parkinson's disease · idiopathic parkinsonism, · secondary parkinsonism (e.g. of post-encephalitic type, of cerebrovascular origin or drug-induced parkinsonism) (see interactions). symmetrel can be given alone for initial therapy or combined with anticholinergic drugsor l-dopa. treatment of infection and prevention of signs and symptoms of infection caused by various strains of influenza a virus · for individual and mass prophylaxis in subjects exposed to risk of infection, particularly when vaccination is unavailable or contraindicated; · post-exposure prophylaxis in conjunction with inactivated vaccine during an outbreak until protective antibodies develop or in patients who are not expected to have a substantial antibody response (immunosuppression); · control of institutional outbreaks. symmetrel does not completely prevent the host immune response to influenza a infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. amantadine is effective in the treatment of active influenza a infection when administered within 48 hours after the onset of symptoms. among paediatric patients, symmetrel is indicated only in children aged 5 years and above.

Європейський Союз - англійська - EMA (European Medicines Agency)

teva pharma b.v. - rivastigmine - dementia; alzheimer disease; parkinson disease - anticholinesterases - symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.

Європейський Союз - англійська - EMA (European Medicines Agency)

novartis europharm limited - rivastigmine - dementia; alzheimer disease; parkinson disease - psychoanaleptics, - symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.

Європейський Союз - англійська - EMA (European Medicines Agency)

cis bio international - ioflupane (123l) - radionuclide imaging; dementia; movement disorders - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. striascan is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy.in adult patients, to help differentiate probable dementia with lewy bodies from alzheimer’s disease. striascan is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Європейський Союз - англійська - EMA (European Medicines Agency)

pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy.in adult patients, to help differentiate probable dementia with lewy bodies from alzheimer’s disease. celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.

Європейський Союз - англійська - EMA (European Medicines Agency)

krka, d.d., novo mesto - rivastigmine - dementia; alzheimer disease; parkinson disease - psychoanaleptics, - symptomatic treatment of mild to moderately severe alzheimer's dementia. symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.,

Європейський Союз - англійська - EMA (European Medicines Agency)

1 a pharma gmbh - rivastigmine - alzheimer disease; dementia; parkinson disease - psychoanaleptics, - symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.

Європейський Союз - англійська - EMA (European Medicines Agency)

hexal ag  - rivastigmine - dementia; alzheimer disease; parkinson disease - psychoanaleptics, - symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.

Європейський Союз - англійська - EMA (European Medicines Agency)

sandoz gmbh - rivastigmine - dementia; alzheimer disease; parkinson disease - psychoanaleptics, - symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.

Європейський Союз - англійська - EMA (European Medicines Agency)

novartis europharm limited - rivastigmine - alzheimer disease; parkinson disease; dementia - psychoanaleptics, - symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.